To address the limited efficacy of α-PD-L1 monotherapy in TNBC, we assessed the potential of DTP-PDT-induced ICD to enhance α-PD-L1 therapy and improve systemic antitumor efficacy in the 4T1 breast cancer model (Figure 5A). The gene discussed is CD274; the disease is breast cancer.